The UK Competition Appeal Tribunal (the “CAT”) has recently issued two judgments relating to anticompetitive practices in the pharmaceutical sector, namely: (1) ‘pay for delay’ agreements in GlaxoSmithKline PLC v Competition and Markets Authority [2018] CAT 4; and (2) excessive pricing in Pfizer Inc. and Pfizer Limited v Competition and Markets Authority [2018] CAT 11.

Downloads –